ÂÜÀòÂÒÂ×

Mark Kleinman is a seasoned project director with extensive experience in the biopharmaceutical and pharmaceutical industries. Currently serving as a Senior Project Director at CSL Behring since January 2020, Mark Kleinman has successfully led teams in developing innovative treatments for hematology conditions and has managed significant projects, including the US launch of HEMGENIX. Prior to this role, Mark Kleinman spent nearly two decades at GSK, advancing from Project Manager to Project Director, where contributions included the establishment of governance processes and the management of diverse R&D projects across multiple therapeutic areas. Earlier positions included postdoctoral research at Columbia University focused on environmental molecular sciences, complemented by a robust academic background with a Ph.D. in Physical Organic Chemistry from the University of Victoria and a BSc in Biochemistry from Concordia University.